ImmunityBio, Inc.
IBRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001326110
In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 2 sales; 405 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $7.54B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.12M in total
- 2
- 13F holdersQ2 2026, +22 vs. previous quarter
- 405
- 13F valueReported value at the end of Q2 2026
- $1.76B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $113.3M
- +668.3% year over year
- Net income, FY2025
- -$351.4M
- No comparable prior period
- Free cash flow, FY2025
- -$308.8M
- No comparable prior period
- Revenue, Q3 FY2026
- $48.8M
- +52.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $351.4M (310.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 122.9M
- Shares sold short
- Change
- −1.15M
- −0.9% vs. previous
- Days to cover
- 7.15
- At average daily volume
Superinvestors holding IBRX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding IBRX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by ImmunityBio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 6, 2026 (view filing)6:06 PM ET | Oct 5 | 1 day | Simon Barry J.Director | SSale | −25.0K | $10.75 | −$268.8K | −0.9%2.78M after | 10b5-1 |
| Oct 6, 2026 (view filing)6:05 PM ET | Oct 2 | 4 days | Cohen CherylDirector | SSale | −81.1K | $10.50 | −$851.1K | −44.7%100.3K after | 10b5-1 |
| Jul 6, 2026 (view filing)8:26 PM ET | Jul 2 | 4 days | Cohen CherylDirector | SSale | −131.2K | $9.50 | −$1.25M | −51.1%125.4K after | 10b5-1 |
| Jul 6, 2026 (view filing)8:25 PM ET | Jul 1 | 5 days | Selecky ChristobelDirector | SSale | −159.5K | $9.02 | −$1.44M | −100.0%0 after | 10b5-1 |
| Jul 1, 2026 (view filing)5:04 PM ET | Jun 29-30 | 2 days | Selecky ChristobelDirector | SSale | −96.7K | $9.01 | −$871.2K | −100.0%0 after | 2 lots10b5-1 |
| Jun 26, 2026 (view filing) | Jun 24 | 2 days | Simon Barry J.Director | SSale | −25.0K | $7.88 | −$197.0K | −0.9%2.80M after | 10b5-1 |
| Jun 5, 2026 (view filing) | Jun 4 | 1 day | Simon Barry J.Director | SSale | −23.0K | $7.18 | −$165.4K | −0.8%2.83M after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24 | 2 days | Simon Barry J.Director | SSale | −75.0K | $12.01 | −$900.8K | −2.6%2.85M after | 10b5-1 |
| Feb 24, 2026 (view filing) | Feb 23 | 1 day | Selecky ChristobelDirector | SSale | −25.0K | $10.00 | −$250.0K | −100.0%0 after | 10b5-1 |
| Feb 24, 2026 (view filing) | Feb 20-23 | 4 days | Simon Barry J.Director | SSale | −175.0K | $10.19 | −$1.78M | −5.6%2.93M after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 405 holdersThe largest institutional positions in ImmunityBio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 34,083,262 | $298.4M | 0.00% | +7,736,819+29.4% | Added |
| State Street Corp | 21,398,438 | $187.3M | 0.01% | +3,690,335+20.8% | Added |
| Vanguard Portfolio Management LLC | 17,863,911 | $156.4M | 0.01% | +1,541,067+9.4% | Added |
| Vanguard Capital Management LLC | 15,691,579 | $137.4M | 0.00% | +563,865+3.7% | Added |
| D. E. Shaw & Co., Inc. | 11,551,019 | $101.1M | 0.06% | −1,020,578−8.1% | Reduced |
| Two Sigma Investments, LP | 11,097,106 | $97.2M | 0.07% | +6,711,606+153.0% | Added |
| Geode Capital Management, LLC | 9,847,896 | $86.2M | 0.00% | +1,815,975+22.6% | Added |
| Millennium Management LLC | 5,579,793 | $48.9M | 0.03% | +4,159,549+292.9% | Added |
| Northern Trust Corp | 3,565,248 | $31.2M | 0.00% | +1,060,467+42.3% | Added |
| Morgan Stanley | 3,432,678 | $30.1M | 0.00% | −586,191−14.6% | Reduced |
Holders of 5% or more of IBRX
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of ImmunityBio, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Cambridge Equities, LP | 13D/A | 64.80%745.5M shares | −1.50 ppfrom 66.30% | Mar 12, 20218 filings | Aug 6, 2026 | SEC |
Politician trades
All politician trades in IBRX2 members of Congress reported 3 trades in ImmunityBio, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Oct 12, 2026 |  Lisa C. McClain House · MI | Buy | $1K-$15K |
| Oct 12, 2026 | Lisa C. McClain House · MI | Buy | $1K-$15K |
| Apr 17, 2023 |  Daniel S. Goldman House · NY | Sell | $1K-$15K |
House · MI · Oct 12, 2026
Buy$1K-$15K
House · MI · Oct 12, 2026
Buy$1K-$15K
House · NY · Apr 17, 2023
Sell$1K-$15K